Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARSUN in relapsed or refractory marginal zone lymphoma
2022-501810-77-00Phase 3Authorised
- Sponsor
- LYSARC
- Start
- Sep 2023
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab and lenalidomide in marginal zone B-cell lymphoma (MZL) (2 arms), sponsored by LYSARC. Primary endpoint: Progression-Free Survival. Planned start Sep 2023; status: authorised.
02
Drugs
mosunetuzumablenalidomide
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2022-501810-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501810-77-00.